Matches in SemOpenAlex for { <https://semopenalex.org/work/W4285393265> ?p ?o ?g. }
- W4285393265 endingPage "1958" @default.
- W4285393265 startingPage "1943" @default.
- W4285393265 abstract "Objective To assess the long‐term safety, tolerability, and efficacy of bimekizumab in patients with active ankylosing spondylitis (AS). Methods Patients with active AS who completed the dose‐ranging, 48‐week BE AGILE randomized controlled trial were eligible to participate in an open‐label extension (OLE) study, in which patients received 160 mg of bimekizumab every 4 weeks. We present the safety and efficacy results through 156 weeks. Missing efficacy data were imputed using nonresponder imputation analysis for binary outcomes and multiple imputation for continuous outcomes. Results From weeks 0–156, 280 of 303 patients (exposure‐adjusted incidence rate 141.0 per 100 patient‐years) experienced ≥1 treatment‐emergent adverse event; the most frequent adverse events were nasopharyngitis (8.1 per 100 patient‐years) and upper respiratory tract infection (5.0 per 100 patient‐years). Additionally, 67 of 303 patients (9.8 per 100 patient‐years) had mild to moderate localized fungal infections (28 of 303 patients had Candida infections [3.7 per 100 patient‐years] and 23 of 303 patients had oral candidiasis [3.0 per 100 patient‐years]), 10 patients had serious infections (1.3 per 100 patient‐years), and no cases of active tuberculosis were reported. Active inflammatory bowel disease (1.1 per 100 patient‐years), anterior uveitis (0.7 per 100 patient‐years), and adjudicated major adverse cardiovascular events (0.3 per 100 patient‐years) were infrequent. The efficacy of bimekizumab treatment demonstrated at week 48 was sustained in the OLE study. At week 156, nonresponder imputation analysis showed that 53.7% of patients (72.6% of observed cases) met the Assessment of SpondyloArthritis international Society criteria for 40% improvement and 28.0% of patients (37.9% of observed cases) achieved partial remission; Ankylosing Spondylitis Disease Activity Scores were reduced from baseline (mean ± SEM 3.9 ± 0.1) to week 48 (2.1 ± 0.1) and week 156 (1.9 ± 0.1) (multiple imputation). Patients showed sustained improvements in pain, fatigue, physical function, and health‐related quality of life. Conclusion The safety profile of bimekizumab was found to be consistent with previously demonstrated findings, and no new safety signals were identified. The efficacy of bimekizumab in patients with AS was sustained through 3 years of treatment." @default.
- W4285393265 created "2022-07-14" @default.
- W4285393265 creator A5003472857 @default.
- W4285393265 creator A5003506967 @default.
- W4285393265 creator A5029965399 @default.
- W4285393265 creator A5034952463 @default.
- W4285393265 creator A5039264064 @default.
- W4285393265 creator A5046013095 @default.
- W4285393265 creator A5050424874 @default.
- W4285393265 creator A5052401121 @default.
- W4285393265 creator A5055643885 @default.
- W4285393265 creator A5064220409 @default.
- W4285393265 creator A5066602987 @default.
- W4285393265 creator A5075710054 @default.
- W4285393265 creator A5077099389 @default.
- W4285393265 creator A5082669130 @default.
- W4285393265 creator A5089158758 @default.
- W4285393265 date "2022-11-07" @default.
- W4285393265 modified "2023-10-17" @default.
- W4285393265 title "Safety and Efficacy of Bimekizumab in Patients With Active Ankylosing Spondylitis: <scp>Three‐Year</scp> Results From a Phase <scp>IIb</scp> Randomized Controlled Trial and Its <scp>Open‐Label</scp> Extension Study" @default.
- W4285393265 cites W1912289137 @default.
- W4285393265 cites W2016850513 @default.
- W4285393265 cites W2030187620 @default.
- W4285393265 cites W2034699258 @default.
- W4285393265 cites W2103874459 @default.
- W4285393265 cites W2110264653 @default.
- W4285393265 cites W2115631255 @default.
- W4285393265 cites W2118293986 @default.
- W4285393265 cites W2140172200 @default.
- W4285393265 cites W2150933492 @default.
- W4285393265 cites W2154662505 @default.
- W4285393265 cites W2166398761 @default.
- W4285393265 cites W2171675095 @default.
- W4285393265 cites W2517289120 @default.
- W4285393265 cites W2572897530 @default.
- W4285393265 cites W2779290422 @default.
- W4285393265 cites W2794845062 @default.
- W4285393265 cites W2885214565 @default.
- W4285393265 cites W2899766103 @default.
- W4285393265 cites W2906054251 @default.
- W4285393265 cites W2912810442 @default.
- W4285393265 cites W2930589497 @default.
- W4285393265 cites W2945268678 @default.
- W4285393265 cites W2947452967 @default.
- W4285393265 cites W2972304813 @default.
- W4285393265 cites W2977162807 @default.
- W4285393265 cites W2982785161 @default.
- W4285393265 cites W2997072819 @default.
- W4285393265 cites W3002825154 @default.
- W4285393265 cites W3004527951 @default.
- W4285393265 cites W3014565220 @default.
- W4285393265 cites W3026296625 @default.
- W4285393265 cites W3031324523 @default.
- W4285393265 cites W3043321092 @default.
- W4285393265 cites W3045768231 @default.
- W4285393265 cites W3115779754 @default.
- W4285393265 cites W3120142450 @default.
- W4285393265 cites W3128034858 @default.
- W4285393265 cites W3128747576 @default.
- W4285393265 cites W3149218144 @default.
- W4285393265 cites W3152821140 @default.
- W4285393265 cites W3154471392 @default.
- W4285393265 cites W3160935903 @default.
- W4285393265 cites W3165456624 @default.
- W4285393265 cites W3185350844 @default.
- W4285393265 cites W4211203343 @default.
- W4285393265 cites W4235489476 @default.
- W4285393265 doi "https://doi.org/10.1002/art.42282" @default.
- W4285393265 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35829672" @default.
- W4285393265 hasPublicationYear "2022" @default.
- W4285393265 type Work @default.
- W4285393265 citedByCount "7" @default.
- W4285393265 countsByYear W42853932652022 @default.
- W4285393265 countsByYear W42853932652023 @default.
- W4285393265 crossrefType "journal-article" @default.
- W4285393265 hasAuthorship W4285393265A5003472857 @default.
- W4285393265 hasAuthorship W4285393265A5003506967 @default.
- W4285393265 hasAuthorship W4285393265A5029965399 @default.
- W4285393265 hasAuthorship W4285393265A5034952463 @default.
- W4285393265 hasAuthorship W4285393265A5039264064 @default.
- W4285393265 hasAuthorship W4285393265A5046013095 @default.
- W4285393265 hasAuthorship W4285393265A5050424874 @default.
- W4285393265 hasAuthorship W4285393265A5052401121 @default.
- W4285393265 hasAuthorship W4285393265A5055643885 @default.
- W4285393265 hasAuthorship W4285393265A5064220409 @default.
- W4285393265 hasAuthorship W4285393265A5066602987 @default.
- W4285393265 hasAuthorship W4285393265A5075710054 @default.
- W4285393265 hasAuthorship W4285393265A5077099389 @default.
- W4285393265 hasAuthorship W4285393265A5082669130 @default.
- W4285393265 hasAuthorship W4285393265A5089158758 @default.
- W4285393265 hasBestOaLocation W42853932651 @default.
- W4285393265 hasConcept C126322002 @default.
- W4285393265 hasConcept C141071460 @default.
- W4285393265 hasConcept C168563851 @default.
- W4285393265 hasConcept C197934379 @default.
- W4285393265 hasConcept C2777402515 @default.
- W4285393265 hasConcept C2778375690 @default.
- W4285393265 hasConcept C2780805593 @default.